NEWS
HCLTech and IBM announce GenAI Center of Excellence
HCLTech and IBM are collaborating to establish Generative AI Center of Excellence ( GenAI CoE ) based on the IBM watsonx AI and data platform .
The CoE , which will be available through HCLTech ’ s AI and Cloud Native Labs in Noida , London and New Jersey and Santa Clara in the US , will help enterprises modernize legacy applications , develop IT service management ( ITSM ) use cases , reduce coding complexity , improve skill development on the IBM watsonx platform and enable continuous innovation .
Alan Flower , EVP , Global Head , AI & Cloud Native Labs , HCLTech , said : “ This expansion of our work with IBM will facilitate rapid exploration of AI ’ s potential as we create highly differentiated HCLTech offerings using the latest IBM technology . We plan to embed watsonx in HCLTech AI Force with GenAI-powered solutions to support code modernization .”
“ Additionally , we plan to help our clients accelerate GenAI adoption through AI facilitated by watsonx while enhancing digital skills for enterprise productivity through the implementation of watsonx Orchestrate .”
Together with IBM , HCLTech aims to train 10,000 of its engineers and architects in IBM ’ s innovative AI technologies , specifically watsonx . The adaptive portfolio , CloudSMART for IBM , assists businesses in continuous innovation through advanced technologies , utilizing the latest business and technology insights .
“ Through this Center of Excellence , we plan to empower our joint clients to rapidly explore , experiment and engineer generative AI solutions with watsonx that are designed to meet their current business challenges ,” said Stephen Smith , General Manager , Service Partners , IBM Ecosystem .
Dhiti Omics now live on SOPHiA DDM
Dhiti Omics Technologies , a precision molecular diagnostics service provider in India , is live on the SOPHiA DDM Platform . The company will use SOPHiA GENETICS ’ technology to enhance its solid tumor testing capabilities .
SOPHiA GENETICS is a cloud-native healthcare technology company and a global leader in data-driven medicine . Dhiti Omics specializes in molecular diagnostic and genetic testing .
By implementing SOPHiA DDM for the Agilent SureSelect Cancer CGP application , Dhiti Omics will improve its ability to provide researchers actionable information on mutations and biomarkers across hundreds of genes .
Sudha N . Rao , PhD , Founder and Director of Dhiti Omics Technologies , said : “ Combining high-quality reagents and powerful analytics into one unique workflow will help us maximize insights from comprehensive genomic profiling data . This will ensure we ’ re delivering the fastest and most accurate diagnostics to our customer base .”
Launched in 2023 , SureSelect Cancer CGP application offers comprehensive genomic profiling .
With the SOPHiA DDM AI Platform , Dhiti Omics will have an integrated solution for rapid and accurate insights on the basis of the latest guidelines reflecting relevant biomarkers .
“ Our Platform and applications are designed to enable companies like Dhiti Omics to more easily advance precision medicine ,” said Ricardo Mendonca Filho , Ph . D ., Managing Director , LAPAC , SOPHiA GENETICS . “ By using SOPHiA DDM , Dhiti Omics can ensure speed and accuracy of solid tumor testing to best support the Indian population .”
16 INTELLIGENTCIO APAC www . intelligentcio . com